KV Pharmaceutical Company (NYSE: KV.A/KV.B) has recently received USFDA approval to market six strengths of Diltiazem HCl ER Capsules through its wholly-owned generic/non-branded subsidiary, ETHEX Corporation.
Diltiazem HCl ER Capsules is the AB rated generic version of Forest Pharmaceuticals, Inc.’s Tiazac®, indicated for the treatment of hypertension (high blood pressure) and angina (chest pain) and belonging to a class of drugs known as calcium channel blockers (CCBs) that lower blood pressure by blocking calcium influx into the smooth muscle cells of the blood vessels.
According to Marc S. Hermelin, Vice Chairman of the Board and Chief Executive Officer stated:
Read the full press release."We are delighted to be extending ETHEX's cardiovascular expertise into the CCB segment with a complete line of AB-rated equivalents to an outstanding product like Tiazac®.
The approval extends ETHEX's line-up of quality ANDA products across multiple therapeutic categories, with several more important opportunities in our pipeline. We are pleased to be able to offer a full line of this important product to our customers and patients."
Comment Preview